HDM2020 for people with advanced solid tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of HDM2020 (FGFR2b-ADC) in Patients With Advanced Solid Tumors

This study will test whether the experimental drug HDM2020 is safe and can shrink tumors in adults with advanced FGFR2-expressing solid tumors.

Quick facts

• Phase: PHASE1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (industry)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Guangzhou, Guangdong)
• Trial ID: NCT07098052 on ClinicalTrials.gov

What this trial studies

This Phase 1 interventional study enrolls adults with advanced or metastatic solid tumors that express FGFR2 and have exhausted or cannot tolerate standard treatments. Participants receive HDM2020 once every three weeks with safety and tolerability as primary endpoints and imaging-based tumor assessments every six weeks to look for antitumor activity. Tumor tissue must be submitted to a central lab for FGFR2 IHC testing before enrollment, and eligible participants must have ECOG performance status 0–1 and adequate organ function. The trial aims to define a safe dose range and gather early signals of efficacy in a biomarker-selected population.

Who should consider this trial

Good fit: Adults (≥18) with advanced or metastatic solid tumors that express FGFR2, ECOG performance status 0–1, adequate organ function, expected survival >3 months, prior standard treatments failed or are unsuitable, and willing to provide tumor tissue for central testing are ideal candidates.

Not a fit: Patients whose tumors do not express FGFR2, who have poor performance status (ECOG ≥2), very limited life expectancy, or who cannot provide required tumor tissue are unlikely to benefit from this study.

Why it matters

Potential benefit: If successful, HDM2020 could offer a new targeted treatment option that helps control tumor growth in patients whose cancers express FGFR2.

How similar studies have performed: Other drugs targeting FGFR pathways have produced responses in some cancers, but HDM2020 is in an early Phase 1 setting and remains largely unproven in humans.

Eligibility criteria

Inclusion Criteria:

1. Participants who understand and voluntarily (or legal guardian) sign a written ICF approved by the Institutional Review Board or Independent Ethics Committee.
2. Male or female participants aged ≥18 years.
3. Participants must be patients with advanced or metastatic malignant solid tumors confirmed by histology or cytology, and have experienced sufficient standard treatment failure, or are intolerant to standard treatment, or have no effective standard treatment.
4. Tumor tissue samples are required to be sent to the central laboratory for IHC testing.
5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1.
6. The expected survival time is \>3 months.
7. According to the RECIST v1.1, participants in Phase Ia must have at least one evaluable lesion, and participants in Phases Ib must have at least one measurable lesion.
8. Laboratory test results during the screening period indicate that the participants have good organ function.
9. Women of childbearing potential (WOCBP) must be willing to use two appropriate barrier methods of contraception from the time of signing informed consent until 7 months after the last dose of study treatment or use barrier contraception plus hormonal contraception to prevent pregnancy, or abstain from heterosexual intercourse throughout the study period; male participants must agree to take adequate contraceptive measures from the first dose of study treatment until 7 months after the last dose of study treatment.
10. Participants with the willingness and ability to complete regular visits, treatment plans, laboratory tests, and other trial procedures.

Exclusion Criteria:

1. Participants with prior treatment with an ADC containing a topoisomerase I (Top I) inhibitor.
2. Participants with active or chronic corneal disorders, history of corneal transplant, keratitis, keratoconjunctivitis, keratopathy, corneal abrasion, inflammation or ulcer, other active eye disorders, and any clinically significant corneal disorders.
3. Participants underwent major surgery within 4 weeks before the first dose; Participants received bone marrow or extensive radiotherapy within 4 weeks before the first dose; received local radiotherapy within 2 weeks before the first dose of the study drug; Participants continuously received systemic corticosteroids; Participants received standard chemotherapy, biological therapy, immunotherapies, any investigational medicinal product (IMP) and other systemic anti-tumor treatments within 4 weeks before the first dose.
4. Participants with active malignant tumors within the past 2 years.
5. Participants not recovered (recovered to ≤ Grade 1 or baseline) from relevant AEs resulting from prior treatments or other anti-cancer therapies.
6. Participants with known active central nervous system (CNS) metastases.
7. Participants with any of the following cardiovascular/cerebrovascular diseases/symptoms/indications: a) Mean resting QTc : ≥470 ms, ECG QTc measured three times within 10 min as the mean value; or those have a history or family history of congenital long QT syndrome; b) Any clinically significant abnormalities in resting ECG in rhythm, conduction, or morphology; c) Left ventricular ejection fraction (LVEF) \<50%; d) Participants with a history of myocardial contraction decreased and exhibited related symptoms within 6 months before study drug administration; e) Hypertension uncontrolled by drug therapy
8. At screening, participants with active syphilis, immunodeficiency disease (HIV), active hepatitis B virus (HBV), or active hepatitis C virus (HCV).
9. Presence of interstitial pneumonia, history of idiopathic pulmonary fibrosis, history of organising pneumonia, history of drug-induced pneumonia, history of idiopathic pneumonia, or evidence of active pneumonia found on chest computed tomography (CT) scan during the screening period; prior use of steroid pulse therapy due to pneumonia; Moderate or severe chronic obstructive pulmonary disease (COPD); Pulmonary malignant lymphangitis.
10. Other diseases that may affect the efficacy and safety of the study drug, including but not limited to: a) Active infection requiring antibiotic therapy occurring within 2 weeks prior to the administration of study drug; b) Active autoimmune diseases or a history of autoimmune diseases; c) History of primary immunodeficiency; d) Active pulmonary tuberculosis; e) Participants who have had a clinically significant haemorrhage or significant haemorrhagic diathesis within 4 weeks before signing the informed consent; f) Any severe or uncontrolled systemic disease.
11. Large amounts or symptomatic moderate amounts of pleural effusion, pericardial effusion, or ascites during the screening period, and still poorly controlled after treatments.
12. Unstable thrombosis events requiring therapeutic intervention within 6 months before screening.
13. A history of solid organ transplant.
14. Known or suspected hypersensitivity to the study drug or its analogues.
15. Pregnant and breastfeeding women.
16. The investigator considers that the participant is not suitable to participate in this study.
17. Participants who have received strong CYP3A4 inhibitors within 1 week before dosing, or are expected to require long-term use of strong CYP3A4 inhibitors during the study intervention period and within 30 days after the last dose.

Where this trial is running

Guangzhou, Guangdong

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (RECRUITING)

Study contacts

• Study coordinator: Ruihua Xu

Conditions: Solid Tumor